Capricor Therapeutics (NASDAQ:CAPR) Coverage Initiated at Alliance Global Partners

Investment analysts at Alliance Global Partners started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR) in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $20.00 price target on the biotechnology company’s stock. Alliance Global Partners’ price objective would indicate a potential upside of 106.19% from the stock’s current price.

CAPR has been the subject of several other reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Oppenheimer dropped their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, June 23rd. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Roth Capital reiterated a “buy” rating and set a $31.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, June 17th. Finally, B. Riley started coverage on shares of Capricor Therapeutics in a report on Thursday, June 26th. They issued a “buy” rating and a $21.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $32.22.

Capricor Therapeutics Trading Down 2.3%

NASDAQ:CAPR opened at $9.70 on Monday. The stock has a market capitalization of $443.10 million, a PE ratio of -6.83 and a beta of 0.82. The firm’s 50 day moving average is $10.76 and its 200 day moving average is $12.29. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. The firm had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. During the same quarter last year, the firm earned ($0.31) earnings per share. Research analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its position in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $68,000. AlphaQuest LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth about $78,000. Finally, New York State Common Retirement Fund boosted its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.